Regenicin, Inc., (OTC Bulletin Board: RGIN.OB) is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin is currently working to bring the product candidate, Regenicin cultured skin substitute, to market. Regenicin cultured skin substitute is an exciting breakthrough technology that uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns and wounds. The company is publicly traded with headquarters in New Jersey.